oxonic acid has been researched along with Neuroendocrine Tumors in 5 studies
Oxonic Acid: Antagonist of urate oxidase.
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both capecitabine alone and capecitabine in combination with temozolomide have activities against neuroendocrine tumors (NETs)." | 7.88 | Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. ( Chi, Y; Zhao, H; Zhao, J, 2018) |
| "Both capecitabine alone and capecitabine in combination with temozolomide have activities against neuroendocrine tumors (NETs)." | 3.88 | Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. ( Chi, Y; Zhao, H; Zhao, J, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ono, H | 1 |
| Kudo, A | 1 |
| Akahoshi, K | 1 |
| Ogura, T | 1 |
| Ogawa, K | 1 |
| Ban, D | 1 |
| Tanaka, S | 1 |
| Tanabe, M | 1 |
| Zhao, J | 2 |
| Zhao, H | 1 |
| Chi, Y | 1 |
| Zhang, H | 1 |
| Shen, G | 1 |
| Zhang, S | 1 |
| Du, F | 1 |
| Cao, Y | 1 |
| Jiang, J | 1 |
| Zheng, F | 1 |
| Ma, X | 1 |
| Wang, Z | 1 |
| Ren, D | 1 |
| Ahmad, R | 1 |
| Zhao, F | 1 |
| Yoshida, Y | 1 |
| Sugawara, N | 1 |
| Minami, T | 1 |
| Iwata, N | 1 |
| Ikeda, K | 1 |
| Endoh, T | 1 |
| Sasano, H | 1 |
| Sato, I | 1 |
| Ueda, N | 1 |
| Kinoshita, E | 1 |
| Minato, H | 1 |
| Ohno, K | 1 |
| Nakaya, N | 1 |
| Shimasaki, T | 1 |
| Nakajima, H | 1 |
| Kosaka, T | 1 |
| Motoo, Y | 1 |
1 review available for oxonic acid and Neuroendocrine Tumors
| Article | Year |
|---|---|
Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Disease-Free Survival; Drug Combinations; Drug Therap | 2018 |
4 other studies available for oxonic acid and Neuroendocrine Tumors
| Article | Year |
|---|---|
Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middl | 2020 |
Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combination | 2018 |
[A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 2013 |
[Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm St | 2010 |